EMERYVILLE, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Mardi C. Dier, Chief Financial Officer of Portola Pharmaceuticals, Inc., to its Board of Directors. Ms. Dier will serve on the Audit Committee. Ms. Dier brings over 25 years of financial management experience in the biotechnology industry. In addition, Adamas announced that Richard H. Booth has retired from the Adamas Board, effective immediately.
"First, I would like to thank Richard for his years of service to Adamas, during which time we brought Adamas public, financed GOCOVRI™ through FDA approval and launch, as well as funded the expansion of our pipeline into multiple sclerosis," said Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. "We welcome Mardi to the Board. Her 25 years of public finance and company building experience will be invaluable as we evolve into a commercial company with the launch of GOCOVRI."
"I am excited to work with the Adamas Board of Directors and management team as the company brings its FDA-approved therapy, GOCOVRI, to patients," said Ms. Dier. "Adamas' unique approach to drug discovery
and development for the treatment of chronic neurological disorders is an exciting area of medicine. I look forward to partnering with the team to help the company reach its long-term goals."
Mardi C. Dier has served as Executive Vice President and Chief Financial Officer of Portola Pharmaceuticals since November 2013 after joining the company in August 2006. At Portola, Mardi has overseen the development of the accounting, finance, global supply chain, investor relations, communications, IT and facilities functions, and has led the raising of over $1.25 billion in capital. Previously, she served as Vice President of Investor Relations at Chiron Corporation from 2003 until its acquisition by Novartis
Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a Director in the West Coast investment banking practice at Prudential Securities, where she focused on biotechnology and other life sciences companies. Ms. Dier was previously at KPMG Peat Marwick in the audit department. She holds a B.S. in biology from Stanford University and an M.B.A. from The Anderson School at the University of California, Los Angeles. In 2013, Ms. Dier was recognized as one of the most influential Bay Area business women by the San Francisco Business Times and was a finalist for its Bay Area CFO of the Year Award.
About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving
levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson's disease; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas' licensed assets are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
Source: Adamas Pharmaceuticals, Inc.
News Provided by Acquire Media